Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06365853
Status:
RECRUITING
Last Update Posted:
2024-04-15
First Post:
2024-04-10
Brief Title:
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Sponsor:
ImmunoGen Inc
Organization:
ImmunoGen Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Folate Receptor-Alpha Positive |
| Recurrent Ovarian Cancer |
Keywords: